Suprachoroidal Injection of Triamcinolone- Review of a Novel Treatment for Macular Edema Caused by Noninfectious Uveitis.
Suprachoroidal Injection of Triamcinolone- Review of a Novel Treatment for Macular Edema Caused by Noninfectious Uveitis.
复制标题
曲安西龙的甲状腺螺体注射 - 对非感染性葡萄膜炎引起的黄斑水肿的新型治疗方法。
DOI：
10.17925/usor.2020.13.2.76
复制
发表时间：
2020
期刊：
影响因子：
--
通讯作者：
Yeh S
中科院分区：
文献类型：
--
作者：
Price KW;Albini TA;Yeh S
黄斑水肿是非感染性葡萄膜炎视力下降的最常见原因。伴有黄斑水肿的非感染性葡萄膜炎的治疗通常包括全身或局部给予皮质类固醇，长期使用受到明显副作用的限制。对具有改善的安全性特征的治疗的需求已经驱动了新型眼科疗法的开发：在脉络膜上腔中施用的专有的曲安奈德混悬液（CLS-TA）（XIPERE™; Clearside Biomedical，Alpharetta，GA，USA）。脉络膜上给予皮质类固醇可使眼后段的类固醇浓度更高，并降低其他眼部不良事件的风险。PEACHTREE试验（ClinicalTrials.gov标识符：NCT 02595398）的最新结果显示，在0周和12周时进行两次脉络膜上注射CLS-TA，随访持续24周的III期试验显示，视力显著改善，中央子场厚度降低，所有这些均未增加眼内压升高或加速白内障进展的风险。
Macular edema is the most frequent cause of visual deterioration in noninfectious uveitis. The treatment of noninfectious uveitis with associated macular edema commonly includes systemic or locally administered corticosteroids, with long-term use limited by significant side effects. The need for a treatment with an improved safety profile has driven the development of a novel ophthalmic therapy: a proprietary triamcinolone acetonide suspension (CLS-TA) administered in the suprachoroidal space (XIPERE™; Clearside Biomedical, Alpharetta, GA, USA). Suprachoroidal delivery of corticosteroids allows higher steroid concentration in the posterior segment and decreases the risk of other adverse ocular events. Recent results from the PEACHTREE trial (ClinicalTrials.gov Identifier: NCT02595398), a phase III trial with two suprachoroidal injections of CLS-TA at 0 and 12 weeks with follow up lasting 24 weeks, showed the significant improvement in visual acuity and reduction in central subfield thickness, all without increasing the risk of elevated intraocular pressure or accelerated cataract progression.